These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1902662)

  • 41. [Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops].
    Zhang JJ; Gao CF; Wang LY
    Zhonghua Yan Ke Za Zhi; 2006 Jul; 42(7):637-41. PubMed ID: 17081425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Penetration into the anterior chamber via the conjunctival/scleral pathway.
    Schoenwald RD; Deshpande GS; Rethwisch DG; Barfknecht CF
    J Ocul Pharmacol Ther; 1997 Feb; 13(1):41-59. PubMed ID: 9029439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Penetration of moxifloxacin through crosslinked corneas.
    Litvin G; Ben Eliahu S; Rotenberg M; Marcovich AL; Zadok D; Kleinmann G
    J Cataract Refract Surg; 2014 Jul; 40(7):1177-81. PubMed ID: 24878254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.
    Gerding PA; Essex-Sorlie D; Vasaune S; Yack R
    Am J Vet Res; 1992 Jun; 53(6):894-6. PubMed ID: 1626779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration.
    Yuan J; Zhai JJ; Chen JQ; Ye CT; Zhou SY
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):345-50. PubMed ID: 19492954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of total hyphemas with urokinase.
    Leet DM
    Am J Ophthalmol; 1977 Jul; 84(1):79-84. PubMed ID: 900222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome.
    Dotan A; Kaiserman I; Kremer I; Ehrlich R; Bahar I
    Br J Ophthalmol; 2014 Feb; 98(2):252-5. PubMed ID: 24276695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of corneal cross-linking on drug penetration in an ex vivo porcine eye model.
    Tschopp M; Stary J; Frueh BE; Thormann W; De Smet J; Van Bocxlaer J; Tappeiner C
    Cornea; 2012 Mar; 31(3):222-6. PubMed ID: 22316648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Collagen shield delivery of amphotericin B.
    Schwartz SD; Harrison SA; Engstrom RE; Bawdon RE; Lee DA; Mondino BJ
    Am J Ophthalmol; 1990 Jun; 109(6):701-4. PubMed ID: 2346199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.
    Cellini M; Baldi A; Possati GL
    Int Ophthalmol; 1994-1995; 18(6):351-3. PubMed ID: 7642335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit.
    Kim MJ; Han ES; Kim J; Kim TW
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):49-53. PubMed ID: 20148650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Etiology of corneal opacities after plasminogen activator-induced fibrinolysis of the anterior chamber].
    Hesse L; Nebeling B; Kauffmann T
    Ophthalmologe; 1999 Jul; 96(7):448-52. PubMed ID: 10479896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of tissue plasminogen activator to revive blebs following intraocular surgery.
    Smith MF; Doyle JW
    Arch Ophthalmol; 2001 Jun; 119(6):809-12. PubMed ID: 11405830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of subconjunctivally injected liposome-encapsulated tissue plasminogen activator on the absorption rate of subconjunctival hemorrhages in rabbits.
    Han SB; Baek SH; Park JS; Yang HK; Kim JY; Kim CK; Hwang JM
    Cornea; 2011 Dec; 30(12):1455-60. PubMed ID: 21955629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model.
    Snyder RW; Lambrou FH; Williams GA
    Arch Ophthalmol; 1987 Sep; 105(9):1277-80. PubMed ID: 3115240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
    Min WK; Kim YB; Lee KM
    Korean J Ophthalmol; 1990 Jun; 4(1):12-5. PubMed ID: 2120486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.
    Mellott MJ; Ramjit DR; Stabilito II; Hare TR; Senderak ET; Lynch JJ; Gardell SJ
    Thromb Haemost; 1995 Mar; 73(3):478-83. PubMed ID: 7545321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Drug release and biocompatibility of cyclosporine A drug delivery system implanting into the anterior chamber].
    Liu ZS; Xie LX; Shi WY; Li SW; Cai Q; Bei JZ; Wang SG
    Zhonghua Yan Ke Za Zhi; 2004 Feb; 40(2):108-12. PubMed ID: 15059564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber.
    Perry HD; Donnenfeld ED; Acheampong A; Kanellopoulos AJ; Sforza PD; D'Aversa G; Wallerstein A; Stern M
    CLAO J; 1998 Jul; 24(3):159-65. PubMed ID: 9684074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topical fluconazole for experimental candida keratitis in rabbits.
    Behrens-Baumann W; Klinge B; Rüchel R
    Br J Ophthalmol; 1990 Jan; 74(1):40-2. PubMed ID: 2306443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.